Shots:
- Novocure reported P-II (PANOVA-4) trial data evaluating Tumor Treating Fields (TTFields) with Tecentriq & gemcitabine/nab-paclitaxel as a 1L treatment for mPDAC, with a median TTFields duration of 25.6wks. & median systemic therapy duration of 6 cycles
- Trial met its 1EP, showing a DCR of 74.4% in TTFields group (N=78) vs 48% with gem/nab-pac alone (N=431) from the historical P-III (MPACT) trial control
- Trial also showed improvements across 2EPs, incl. ORR of 34.6% & mOS of 9.7mos. Additional 2EPs incl. PFS, one-year survival rate, 6mos. PFS, DoR, & rate of TRAEs; additional data to be presented at future conference
Ref: Businesswire | Image: Novocure| Press Release
Related News: Novocure Receives the US FDA Approval of Optune Pax with CT for Pancreatic Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
